More recently, insulin treatment initiation in T2D patients treated with metformin alone for a median of 14 months led to an increase of a composite end point including cardiovascular events and all-cause mortality but had no effect on cardiovascular mortality alone [16]. This evidence concerns the gene INS and type 2 diabetes mellitus.